CHDI
Huntington’s Disease Society of America and CHDI Foundation launch HD Legacy to promote brain donation for HD research
New York, NY, June 20, 2019 – In response to a growing need to study exactly what Huntington’s disease (HD) does to the human brain, the Huntington’s Disease Society of America (HDSA) and CHDI Foundation are pleased to announce ...Read More
Charles River Laboratories and CHDI Foundation extend Huntington’s disease collaboration
WILMINGTON, Mass. – April 9, 2019 — Charles River Laboratories International, Inc. (NYSE: CRL) and CHDI Foundation today announced a five-year extension of their ongoing collaboration. The organizations began working together in ...Read More
New Enroll-HD clinical dataset now available
December 18, 2018 – A new data cut from the Enroll-HD observational study, named periodic dataset 4 (PDS4), was made availab ...Read More
CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics
Pomezia, Italy, November 19th 2018 – IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, ...Read More
C-Path, CHDI and CDISC announce Therapeutic Area User Guide for Huntington’s disease
TUCSON, Ariz., NEW YORK and AUSTIN, Texas, November 1, 2018 — The Huntington’s Disease Regulatory Science Consortium (HD-RSC), lau ...Read More
Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington’s disease
Strategic alliance with CHDI to accelerate development of drugs for Huntington’s disease One of the largest strategic drug discovery alliances within Evotec Hamburg, Germany, 30 August 2018: Evotec AG (F ...Read More
PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease
European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options RG6042 has the potential to be the fi ...Read More
PTC Therapeutics and CHDI Foundation Announce a Collaboration on a Small-Molecule Therapeutic for Huntington’s Disease
SOUTH PLAINFIELD, N.J., April 4, 2018 – PTC Therapeutics, Inc. (NASDAQ: PTCT) and the CHDI Foundation, Inc. (CHDI) today announced a research collaboration to advance PTC’s Huntington’s disease program. The program is optimizin ...Read More
C-Path and CHDI launch consortium to accelerate development of Huntington’s disease therapies
Tucson, AZ, and New York, NY – March 28, 2018 – The Critical Path Institute (C-Path), together with CHDI Foundation, Inc. (CHDI), today announced the off ...Read More
Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington’s Disease
Dose-dependent Reductions of Mutant Huntingtin Protein Observed Ionis Earns $45 Million License Fee CARLSBAD, Calif., Dec. 11, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Roche has exercis ...Read More